Nucleoside transport inhibitor, dipyridamole, induced myocardial protection following hemorrhagic shock in ex vivo perfused rat hearts  by Soliman, Mona
Journal of the Saudi Heart Association (2011) 23, 75–80King Saud University
Journal of the Saudi Heart Association
www.ksu.edu.sa
www.sha.org.sa
www.sciencedirect.comFULL LENGTH ARTICLENucleoside transport inhibitor, dipyridamole, induced
myocardial protection following hemorrhagic shock
in ex vivo perfused rat heartsMona Soliman *Department of Physiology, College of Medicine, King Khalid University Hospital, P.O. Box 2925 (29), Riyadh 11461, Saudi ArabiaReceived 21 September 2010; revised 28 December 2010; accepted 2 January 2011
Available online 8 January 2011*
E
10
El
Pe
doKEYWORDS
Hemorrhage;
Rat;
Dipyridamole;
Isolated hearts;
Myocardial protectionTel.: +966 1 4671047; fax:
-mail address: monaslmn@y
16-7315 ª 2011 King Saud
sevier B.V. All rights reserve
er review under responsibilit
i:10.1016/j.jsha.2011.01.004
Production and h+966 1
ahoo.com
Universit
d.
y of King
osting by EAbstract Introduction: Successful protection against post-resuscitation myocardial injury is not
available for trauma patients. Whereas intensive improvement in resuscitation strategies reduce
myocardial injury, death among trauma patients are among the highest in the world due to myo-
cardial dysfunction and multiple organ failure. Dipyridamole is a nucleoside transport inhibitor.
Recent studies have shown that elevation of serum adenosine caused by dipyridamole improve car-
diac function. The purpose of the present study was to examine the myocardial protective effects of
dipyridamole therapy following 1 h of hemorrhagic shock.
Methods: Sprague–Dawley rats were used. The study consisted of three phases: Phase I to examine
the direct effects of dipyridamole on myocardial function by perfusion of the isolated hearts with
Krebs Henseleit buffer (KHB) + dipyridamole on the Langendorff apparatus. Phase II examined
the protective effects of dipyridamole following 60 min of hemorrhagic shock (HS) by ex vivo treat-
ment with dipyridimole 20 lg/L for 5 min followed by resuscitation with KHB for 55 min. Phase
III: 60 min HS followed by in vivo treatment by injecting 1 ml of (20 lg/L) dipyridamole intra-arte-
rially, and resuscitation for 30 min. Myocardial protection was assessed by measuring left ventric-
ular generated pressure (LVGP) and end diastolic pressures (LVEDP).
Results: During ex vivo resuscitation, hearts from dipyridamole treated animals had signiﬁcantly
higher LVGP, and signiﬁcantly lower LVEDP versus controls.46725672.
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76 M. SolimanConclusion: Dipyridamole therapy produces protection against post-resuscitation myocardial
injury in rats.
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Emergent resuscitation therapies have improved survival after
trauma (Crookes et al., 2004). Unfortunately, these resuscita-
tion therapies are rarely carried out before considerable myo-
cardial dysfunction and injury has occurred. This has led
researchers for identifying therapies that protect against
post-resuscitation myocardial injury.
Several lines of evidence suggest that nucleoside transport
inhibitors, which increase adenosine levels by inhibiting uptake
into myocyte, might offer protection against ischemia–reperfu-
sion injury (Gokgoz et al., 1992). Adenosine is rapidly taken
up by cells via nucleoside transporter in the cell membrane.
Adenosine has cardioprotective effects: it activates adenosine
receptors, resulting in attenuation of catecholamine release, b
adrenoceptor-mediated myocardial hypercontraction, and
Ca2+ overload via A1 receptors, and increases coronary blood
ﬂow and inhibits platelet and leukocyte activation via A2
receptors (Gresele et al., 1986).
Nucleoside transport inhibitors, including dipyridamole
(Auchampach and Gross, 1993; Amrani et al., 1992), reduce
ischemia–reperfusion injury when infused immediately before
experimental myocardial infarction. In recent studies, eleva-
tion of serum adenosine by administration of dipyridamole
improved cardiac function in patients with heart failure
(Strauer et al., 1996; Bedetti et al., 2005). However, the cardio-
protective effects of nucleoside transport inhibitors following
resuscitation of hemorrhagic shock are unknown.
The present study examined the myocardial protective
effects of adenosine transport inhibitor, dipyridamole, on myo-
cardial contractile function and structure following hemor-
rhagic shock and resuscitation.2. Materials and methods
This study was approved by the Continuous Medical Research
Center at the College of Medicine, King Saud University. Male
Sprague–Dawley rats (450–500 GWT) were used. The study
consisted of three phases to which rats were randomly assigned:
Phase I was designed to examine the direct effects of dipyridam-
ole on myocardial function by perfusion of the isolated hearts
with Krebs Henseleit buffer (KHB) + dipyridamole for 5 min
then KHB for 55 min on the Langendorff apparatus. Phase II
examined the protective effects of dipyridamole following
60 min of hemorrhagic shock (HS) by ex vivo treatment with
dipyridimole 20 lg/L for 5 min then KHB for 55 min. Phase
III: examined the protective effects of in vivo treatment with
dipyridamole following 60 min HS by injecting 1 ml of (20 lg/
L) dipyridamole intra-arterially, and resuscitation for 30 min.
2.1. Phase I: effects of dipyridamole on myocardial function in
the isolated perfused hearts
Rats were injected intra-peritonealy (i.p.) with heparin sodium
2000 I.U. 15 min prior to anesthesia. The rats were thenanaesthetized using urethane 125 mg/kg intra-peritonealy. Rats
were randomly assigned to either: (1) control group: of 60 min
perfusion with Krebs solution in the Langendorff system, or
(2) dipyridamole treated group: perfusion of the isolated hearts
with 20 lg/L Dipyridamole + Krebs for 5 min, then shifted to
perfusion with Krebs solution for 55 min (n= 6 per group).
2.1.1. Isolated heart perfusion
Hearts were excised quickly and rapidly placed onto a Lange-
ndorff system for perfusion in retrograde mode via the aorta;
at a rate of 10 mL/min. Hearts were perfused with two solu-
tions: (1) Krebs solution; (2) Krebs + dipyridamole 20 lg/L.
KHB of the following composition (in mM): sodium chloride,
118; calcium chloride, 1.25; potassium chloride, 4.7; sodium
bicarbonate, 21; magnesium sulphate, 1.2; glucose, 11;
potassium biphosphate, 1.2; and EDTA, 0.5. An apical stab
incision was made in the left ventricle (LV) using a # 15 scalpel
blade. A saline-ﬁlled cellophane balloon-tipped catheter was
placed into the LV via the mitral valve and was used to mea-
sure LV pressure and balloon volume. LV and perfusion pres-
sures were measured using transducers placed at the levels of
the heart and aorta. Hearts were stimulated electrically at
5 Hz using electrical stimulator (6020 Stimulator from Har-
vard Apparatus). Perfusion pressure was maintained at
50 mmHg. LVEDP was maintained at 5 mmHg. Perfusate
temperature was maintained at 37 C. The perfusate was
gassed with a mixture of 95% O2 + 5% CO2 at a pH of 7.4
for the duration of the experiment.
2.2. Phase II: ex vivo treatment with dipyridamole following
hemorrhagic shock
Rats were randomly assigned to: (1) hemorrhage, (2) hemor-
rhage + dipyridamole, (3) sham hemorrhage and (4) sham
hemorrhage + dipyridamole groups (n= 6 per group). Rats
were hemorrhaged using a reservoir model. The left carotid ar-
tery was cannulated using polyethylene tubing size 60, and was
connected to an in-line pressure transducer for continuous
blood pressure monitoring. Animals were allowed to stabilize
for a period of 30 min. Arterial blood pressure was monitored
for 1 h. In the hemorrhage group, blood was withdrawn to
reach mean arterial blood pressure of 40 mmHg, via an in-
tra-arterial catheter inserted into the left carotid artery. In
the sham hemorrhage group, the same surgical procedure
was performed without hemorrhage. Isolated hearts were
resuscitated ex vivo either with KHB solution for 60 min, or
20 lg/L dipyridamole + KHB for the ﬁrst 5 min then KHB
for 55 min.
2.3. Phase III: in vivo resuscitation following 1 h of hemorrhagic
shock
Rats were randomly assigned to: (1) hemorrhage, (2) hemor-
rhage + dipyridamole, (3) sham hemorrhage and (4) sham
hemorrhage + dipyridamole groups (n= 6 per group). Rats
Figure 1 (A) Left ventricular generated pressure (LVGP) and (B) positive change in pressure over time (+dP/dt) in the isolated perfused
hearts in the dipyridamole + KHB and the KHB perfused hearts (n= 6 per group). All values are means ± SD. *Represents p< 0.05
versus perfusion with KHB only (n= 6 per group).
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in vivo by reinjecting the shed blood to restore normotension.
In the treated group, rats were injected intra-arterially with
dipyridamole then resuscitated. After 60 min, hearts were iso-
lated and perfused with KHB for measurement of myocardial
function.
2.4. Hemodynamic and cardio dynamic measurements
Left ventricular end diastolic pressure (LVEDP) and the left
ventricular peak systolic pressure (LVPSP) were measured
continuously. Left ventricular generated pressure (LVGP)
was calculated.
2.5. Statistical analysis
Data were initially analyzed with Bartlett’s test for homogene-
ity. Data found not to be homogeneous were transformed and
reanalyzed. Data are presented as means and standard devia-
tions or standard errors. Data were analyzed with multivariate
analysis of variance (ANOVA). Means were analyzed usingDuncan’s test. Data were considered signiﬁcant when yielding
a p value <0.05.3. Results
In isolated perfused hearts, treatment with dipyridamole has
been shown to induce positive ionotropic effect in the isolated
perfused hearts. Fig. 1A and B show the changes in the left
ventricular generated pressure and max + dP/dt during
ex vivo perfusion of the hearts in the Langendorff system for
1 h with KHB only or dipyridamole treated. Left ventricular
generated pressure and max + dP/dt were signiﬁcantly higher
in the dipyridamole perfused group as compared to the hearts
perfused with only KHB (p< 0.05).
As shown in Fig. 2A and B, left ventricular generated pres-
sure and max + dP/dtwere signiﬁcantly improved after 60 min
of ex vivo perfusion in hearts treated with dipyridamole com-
pared to hearts perfused with normal physiological KHB buffer
as well as to sham control group (p< 0.05). These data suggest
that dipyridamole therapy before resuscitation following
Figure 2 (A) Left ventricular generated pressure (LVGP) in the sham, hemorrhagic shock and hemorrhagic shock + dipyridamole and
(B) positive change in pressure over time (+dP/dt) in ex vivo resuscitated hearts in the Langendorff system with KHB only or
KHB+ dipyridamole following 1 h of experimental protocol (n= 6 per group). All values are means ± SD. *Represents p< 0.05 versus
hemorrhagic shock group, represents p< 0.05 versus hemorrhagic shock group (n= 6 per group).
78 M. Solimanhemorrhagic shock improved contractile function in the ex vivo
perfused hearts in the Langendorff system.
As shown in Fig. 2A and B, left ventricular generated pres-
sure and max + dP/dt were signiﬁcantly lower in hearts from
hemorrhagic shock animals perfused with KHB only com-
pared to hearts from sham group (p< 0.05). This shows that
myocardial contractile function is decreased following resusci-
tation of hemorrhagic shock (see Fig. 3).
4. Discussion
The purpose of this study was to determine the myocardial
protective effects of dipyridamole following hemorrhagic
shock in isolated perfused hearts as well as in the in vivo trea-
ted animals. Dipyridamole increased the myocardial contrac-
tility in the isolated perfused hearts. Hemorrhagic shock
results in myocardial dysfunction. Successful resuscitation fol-
lowing hemorrhagic shock requires complete recovery of myo-
cardial function. This can be achieved by increase in
contractility mediated by pharmacological vasodilatation of
coronary bed (Stahl et al., 1986).
Dipyridamole inhibits the transport of extracellular adeno-
sine into the cells resulting in increased extracellular adenosine,which provides protection against post-resuscitation myocar-
dial injury (Gresele et al., 1986).
The mechanisms by which dipyridamole can improve myo-
cardial contractility following hemorrhagic shock and resusci-
tation are not completely understood. The most likely
mechanism is the dipyridamole induced increase in blood ﬂow
and vascular wall within the ventricular wall, which in turn
leads to a stretching of myocardial ﬁbers and to an increase
in contractility through the Frank–Starling effect.
Experimental studies support the concept that vasodilators
may reduce ischemia by increasing collateral blood ﬂow to
ischemic myocardium (Cohen et al., 1973).
Vasodilator-induced hypotension is generally beneﬁcial be-
cause of the associated decrease in an LV wall tension, but an
excessive reduction in perfusion pressure may be harmful (Kat-
tus and Gregg, 1959).
Other possible mechanisms are sympathetic activation sec-
ondary to the systemic vasodilatation or a decrease of ventric-
ular afterload (Picano et al., 1992; Lucarini et al., 1992).
In addition, dipyridamole has documented anti-inﬂamma-
tory properties, including antioxidant effects (Weyrich et al.,
2005). Dipyridamole potentiates synthesis of nitric oxide, a
vasodilating antioxidant molecule that prevents abnormal
Figure 3 (A) Left ventricular generated pressure (LVGP) in the sham, hemorrhagic shock and hemorrhagic shock + dipyridamole and
(B) positive change in pressure over time (+dP/dt) in the in vivo dipyridamole treated rats and resuscitated isolated hearts in the
Langendorff system with KHB only following 1 h of experimental protocol (n= 6 per group). All values are means ± SD. *Represents
p< 0.05 versus hemorrhagic shock group, represents p< 0.05 versus hemorrhagic shock group (n= 6 per group).
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extracellular adenosine levels resulting from extended-release
dipyridamole treatment also affect the expression of inﬂamma-
tory factors. Healthy vascular endothelium produces adeno-
sine that minimizes the inﬂammatory response. Elevated
adenosine levels inhibit neutrophil activation and associated
superanion production. Reduced expression of adhesion mole-
cules (CD11/ CD18, MAC-1, b2-integrins) on neutrophils
and polymorphonuclear cells has also been shown to occur
(Wollner et al., 1993).
Dipyridamole has been reported to attenuate nuclear factor
jB transcription in monocytes. Dipyridamole treatment also
reduced expression of monocyte chemotactic protein-1 and
matrix metalloproteinase-9 (Weyrich et al., 2005). Monocyte
chemotactic protein-1 attracts monocytes to the athero-
sclerotic region and promotes atherosclerosis (Charo and
Taubman, 2004). Reduction of matrix metalloproteinase-9
is of particular interest because matrix metalloproteinase-9 is
associated with unstable plaques and has been found to be
elevated in carotid plaques from patients with TIA and stroke
(Verhoeven et al., 2005).
Another way of evaluating the effects of dipyridamole on
circulating levels of inﬂammatory markers, which may reﬂectabnormal responses occurring at the vessel wall (Libby and
Theroux, 2005).
5. Summary
Based on the results of previous experimental and clinical stud-
ies, the present study showed that dipyridamole protects the
myocardium against post-resuscitation myocardial dysfunc-
tion and failure.Acknowledgments
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